Capping off a busy 2023, Insilico Medicine has announced a potentially first-in-class oral PHD inhibitor for the treatment of inflammatory bowel disease (IBD). ISM5411 is the fifth AI-backed drug candidate from Insilico Medicine to reach clinical stages. ISM5411 targets prolyl hydroxylase domain (PHD) enzymes via modulation of the hypoxia-inducible factor (HIF) pathway, which is involved…
Using AlphaFold, Insilico Medicine produces AI drug discovery in record time
An international group of researchers employed DeepMind’s deep learning-driven AlphaFold protein structure database to design and synthesize a potential hepatocellular carcinoma (HCC) drug in only 30 days. The AI drug discovery project consisted of Insilico Medicine, the University of Toronto’s Acceleration Consortium and researchers including Nobel laureate Michael Levitt. The team applied AlphaFold to Insilico’s…
Fueling breakthroughs in pharma AI: 3 critical factors
Big data and AI offer massive opportunities to the pharmaceutical industry — in theory. In reality, many companies are struggling to realize the potential of these tools. Some organizations have been hesitant or resistant to leveraging the technologies. Others may have attempted to embrace them early on but are now beginning their second or third…